Genetic Disorders: Latest News, Top Stories & Analysis

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced the progression of its OCU410ST GARDian clinical trial after the Data and Safety Monitoring Board (DSMB) approved moving forward with …

Regional

Harmony Biosciences Launches Phase 3 Trial for Potential Prader-Willi Syndrome Treatment

April 8, 2024April 7, 2024 - by Timothy Alexander

PLYMOUTH MEETING, PA — In a significant development for patients with Prader-Willi syndrome (PWS), Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) recently announced the initiation of a global Phase 3 registrational …